ImmunityBio, Inc.
ImmunityBio, Inc. (Nasdaq: IBRX) is a biotechnology company that develops and commercializes immunotherapies intended to activate the immune system against cancer and infectious diseases. Its approved product, ANKTIVA, is an IL-15 receptor superagonist approved for use with BCG in adults with BCG-unresponsive… From the company’s description.
Over the twelve months to Jun 30, 2026, ImmunityBio, Inc. reported revenue of $165.79M, up 192.9% from a year earlier, and a net loss of $992.42M. Its operating margin was −151.9%, and operations used $281.14M in cash. In fiscal 2025, it reported revenue of $113.29M, up 668.3% from fiscal 2024, and a net loss of $351.47M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ImmunityBio, Inc. does
In the company’s own words
ImmunityBio, Inc. (Nasdaq: IBRX) is a biotechnology company that develops and commercializes immunotherapies intended to activate the immune system against cancer and infectious diseases. Its approved product, ANKTIVA, is an IL-15 receptor superagonist approved for use with BCG in adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; it also has conditional approval in Saudi Arabia for use with checkpoint inhibitors in metastatic non-small cell lung cancer. The company’s Cancer BioShield platform combines cytokine fusion proteins with adenovirus-vectored vaccines, off-the-shelf and patient-derived natural killer cell therapies, and other immune modulators. Its vaccine candidates target tumor antigens and infectious agents, while its cell therapy programs include CAR-NK candidates and memory-like cytokine-enhanced NK cells. ImmunityBio serves patients through its commercial product and develops additional therapies for cancer and infectious disease indications. It reported approximately $113 million in net product revenue for fiscal 2025. Its brands include ANKTIVA, haNK, taNK, and QUILT. Its website is https://immunitybio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1326110
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ImmunityBio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ImmunityBio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ImmunityBio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ImmunityBio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ImmunityBio, Inc.'s last four quarterly filings that the numbers alone won't show?”